Keythera Pharma Press Release : KF-0210 Delivers Rapid, Deep, and Durable Symptom Relief in Phase IIa Knee Osteoarthritis Study.
World’s first oral EP4 antagonist to enter clinical development for OA and chronic pain management.
Phase IIa Clinical Highlights
Rapid onset: Some patients experienced meaningful pain relief by Day 8.
Deep pain reduction: 60–75% improvement in WOMAC Pain by Day 15, substantially higher than the 30–40% reported for celecoxib at a similar timepoint.
Functional improvement: WOMAC stiffness and physical function scores improved in parallel with pain relief.
Strong safety and tolerability: Across Phase I trials (China & Australia), no DLTs were observed; mean exposure reached 17 weeks, with maximum duration exceeding 95 weeks. The Phase IIa study confirmed excellent tolerability in OA patients.
Mechanistic advantage: Selective blockade of the PGE₂–EP4 pathway enables dual action on inflammatory pain and cartilage matrix protection, potentially overcoming NSAIDs’ limitations.
Mechanistic Innovation: Beyond the Ceiling of NSAID Efficacy
NSAIDs reduce prostaglandin synthesis but are constrained by COX-1/COX-2–related toxicities and a therapeutic ceiling.
KF-0210, a highly selective EP4 antagonist, does not inhibit COX enzymes, allowing:
Faster onset
Deeper and more durable symptom improvement
Suitability for long-term treatment
Osteoarthritis & Chronic Pain: A Global Unmet Need
Osteoarthritis & Chronic Pain: A Global Unmet Need
Chronic pain is one of the top drivers of global disease burden; the market exceeds tens of billions USD annually.
OA is the largest single chronic pain indication, affecting 600+ million patients worldwide.
Current therapies deliver modest benefit (30–40% relief), carry safety limitations, and do not address cartilage degeneration.
EP4: A Central Pain Mechanism Across Multiple Conditions
The PGE₂–EP4 pathway plays a pivotal role in sensitization, inflammation, and tissue damage across chronic pain states.
Based on its mechanism, KF-0210 may extend into additional high-impact indications such as:
Chronic low back pain (CLBP)
Axial spondyloarthritis / ankylosing spondylitis (axSpA / AS)
Chronic postoperative pain
Next Steps
Keythera will advance:
A multicenter, randomized Phase IIb trial
Global co-development and licensing discussions
Data presentations at OARSI and ACR 2026
KF-0210 aims to become a globally innovative therapy, delivering safe, effective, and long-term treatment options for hundreds of millions living with osteoarthritis and chronic pain.
BD@keytherapharma.com
www.keytherapharma.com
Suzhou — Keythera Pharma today announced positive results from a Phase IIa exploratory study of KF-0210, the first oral EP4 antagonist to enter human clinical trials for osteoarthritis (OA) and chronic pain. The study demonstrated rapid onset, deep pain reduction, and sustained functional improvement, suggesting KF-0210 may exceed the traditional efficacy ceiling observed with NSAIDs.
0512-63020039
info@keytherapharma.com
Unit B2-508, Bio-Bay, 218 Xinghu Street, SIP, Suzhou, Jiangsu, China
苏公网安备32059002005508号
